Varghese M, Khan A J, Quaye G, Patel U, Kumar K, Evans H E
Chemotherapy. 1982;28(6):417-20. doi: 10.1159/000238132.
Moxalactam, a new beta-lactam antibiotic was evaluated in the treatment of 21 pediatric patients including 16 with clinical and radiological evidence of pneumonia and 5 with urinary tract infection (UTI). Clinical and radiological resolution of pneumonia occurred in all. Bacteriological efficacy in pneumonia, however, was assessed in only 1 patient whose blood culture grew H. influenzae type b. In patients with UTI, the therapy was successful, bacteriologically as well as clinically. The only side effects observed were mild transient elevation of SGOT and alkaline phosphatase in 6 cases. The peak and trough levels of the drug were manyfold higher than the known minimum inhibitory concentrations of common pathogens. The mean t1/2 projected of 95 and 124 min with intravenous and intramuscular route, respectively, were similar to those reported in adults.
莫西拉坦是一种新型β-内酰胺类抗生素，对21例儿科患者进行了评估，其中16例有肺炎的临床和影像学证据，5例有尿路感染（UTI）。所有肺炎患者的临床和影像学症状均得到缓解。然而，仅对1例血培养出b型流感嗜血杆菌的肺炎患者评估了细菌学疗效。对于UTI患者，治疗在细菌学和临床上均取得成功。观察到的唯一副作用是6例患者出现轻度短暂性谷草转氨酶和碱性磷酸酶升高。该药物的峰浓度和谷浓度比常见病原体已知的最低抑菌浓度高许多倍。静脉注射和肌肉注射途径的平均半衰期分别预计为95分钟和124分钟，与成人报告的相似。
